China-based diagnostic reagents specialist, Pilot Gene Technology (Hangzhou) Co., Ltd, has reportedly raised RMB 100 million (USD 13.8 million) in a Series B financing round led by Simao Capital. The funds raised will be directed towards the research and development of fully automated instruments and equipment, including Point-of-Care Testing (POCT), Category III reagents, and the expansion of the company’s overseas business.
Digital PCR Technology and Its Applications
Digital PCR (dPCR) is an absolute quantitative technique for nucleic acid molecules and represents the third generation of nucleic acid detection technology, following ordinary PCR and fluorescence quantitative PCR. It is recognized as one of the most sensitive nucleic acid quantification methods currently available. Pilot Gene has capitalized on this technology to launch detection kits for a variety of scientific research applications, including infection, tumor, and reproductive genetics, utilizing its multicolor fluorescence channel number dPCR platform.
Implications for the Diagnostic Industry
The successful Series B financing round positions Pilot Gene Technology to enhance its product offerings and expand its reach in the global diagnostics market. The investment in dPCR technology and the development of new instruments and equipment are set to strengthen the company’s competitive edge in the field of molecular diagnostics.-Fineline Info & Tech
